Arimidex Tablet 1 mg

Χώρα: Ιορδανία

Γλώσσα: Αγγλικά

Πηγή: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Δραστική ουσία:

Anastrozole 1 mg

Διαθέσιμο από:

مستودع ادوية شاوي و رشيدات و مسنات - Shawi & Rushedat Drug Store

Φαρμακολογική κατηγορία (ATC):

L02BG03

INN (Διεθνής Όνομα):

Anastrozole 1 mg

Δοσολογία:

1 mg

Μονάδες σε πακέτο:

28

Κατασκευάζεται από:

ASTRA ZENECA PHARM/USA (امريكا)

Περίληψη προϊόντος:

44.69 :سعر الجمهور + الضريبة

Φύλλο οδηγιών χρήσης

Page 1 of 12
ARIMIDEX 1 MG
_anastrozole_
FILM-COATED TABLETS
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 1 mg anastrozole.
For excipients see List of excipients.
PHARMACEUTICAL FORM
Film-coated tablet.
White, round, biconvex tablet with logo on one side and strength on
the other.
THERAPEUTIC INDICATIONS
Adjuvant treatment of post-menopausal women with hormone receptor
positive early invasive
breast cancer.
Adjuvant treatment of early breast cancer in hormone receptor positive
post-menopausal women
who have received 2 to 3 years of adjuvant tamoxifen.
Treatment of advanced breast cancer in post-menopausal women. Efficacy
has not been
demonstrated in oestrogen receptor negative patients unless they had a
previous positive clinical
response to tamoxifen.
POSOLOGY AND METHOD OF ADMINISTRATION
Adults including the elderly
:
One 1 mg tablet to be taken orally once a day.
Children
:
Not recommended for use in children (see
Pharmacodynamic and Pharmacokinetic properties).
Renal Impairment
:
No dose change is recommended in patients with
mild or moderate renal impairment.
Hepatic Impairment
:
No dose change is recommended in patients with
mild hepatic disease.
For early disease, the recommended duration of treatment should be 5
years.
Page 2 of 12
CONTRAINDICATIONS
Arimidex is contraindicated in:
- pre-menopausal women
- pregnant or lactating women
- patients with severe renal impairment (creatinine clearance less
than 30 ml/min)
- patients with moderate or severe hepatic disease
- patients with known hypersensitivity to anastrozole or to any of the
excipients as
referenced in the List of excipients.
Co-administration of tamoxifen or oestrogen-containing therapies with
Arimidex should be
avoided as this may diminish its pharmacological action (see
Interactions with other medicinal
products and other forms of interaction).
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Arimidex is not recommended for use in children as safety and efficacy
have not been established
in this group of patients (see Pharmacodynamic